$10.75
arrow_drop_down2.18%Key Stats | |
---|---|
Open | $10.81 |
Prev. Close | $10.96 |
EPS | -2.35 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 10.31 | 11.11 |
52 Week Range | 7.41 | 24.17 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -2.35 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology to Participate in Jefferies Global Healthcare Conference
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
2 Incredible Growth Stocks to Buy Hand Over Fist